Australia's Neuren Pharma gains on US FDA 'fast track' tag for Pitt Hopkins drug

Neuren Pharmaceuticals

19/02/2025 04:59

** Shares of Neuren Pharmaceuticals  NEU.AX  rise 4.1% to
A$13.61
    ** Stock hits highest level in a week
    ** Drug manufacturer says US Food and Drug Administration
(FDA) has granted Fast Track designation for NNZ-2591 to treat
Pitt Hopkins syndrome (PTHS)
    ** FDA's "Fast Track" status facilitates development and
expedites the review of drugs to treat serious condition
    ** Pitt Hopkins syndrome is a genetic condition that affects
brain and nervous system
    ** Stock up 4.6% this year, as of last close

 (Reporting by Sherin Sunny in Bengaluru)
 ((Sherin.Sunny@thomsonreuters.com;))